



Solar 1

What is Solar 1 and Solar 2?

Solar 1 is a prototype for Solar 2. Solar 1 is planned to be the first building in NYC to generate power in excess of what it uses, thereby putting more power into the grid than it takes out. It will be a landmark and a model for future NYC buildings.

What is Solar One?

By catalyzing new ways of living and working that respond to a world affected by climate change, Solar One is transforming the way people think about energy, the urban environment, and resilience. Solar One strives to bring those most affected by environmental injustice to the forefront of developing and benefitting from the clean energy economy.

What is the Solar One environmental education center?

The Solar One Environmental Education Center will be a model of resiliency for hurricanes, storm surges, and other potential emergency conditions. The Center will be an education destination for thousands of NYC public school children who participate in our Green Design Lab programs each year.

Who designed the Solar-1 trial?

The SOLAR-1 trial was designed and overseen by a steering group of medical oncology experts, including representatives from the trial sponsor (Novartis). The protocol was designed by the steering committee, which included the primary investigator.

Who approved the Solar-1 trial?

The original trial protocol and subsequent amendments were approved by an independent ethics committee and institutional review board at each site. The SOLAR-1 trial was designed and overseen by a steering group of medical oncology experts, including representatives from the trial sponsor (Novartis).

Does the Solar-1 trial cross the O'Brien-Fleming efficacy boundary in postmenopausal patients?

Although the SOLAR-1 trial did not cross the prespecified O'Brien-Fleming efficacy boundary in postmenopausal patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative advanced breast cancer, alpelisib and fulvestrant nevertheless prolonged the median OS.

Phosphatidylinositol 3-kinase (PI3K) pathway hyperactivation due to PIK3CA mutations contributes to poor survival in patients (pts) with HR+, HER2- ABC (Mosele 2020). In the phase III SOLAR-1 trial of pts with progression on/after aromatase inhibitor (AI), the PI3K? inhibitor ALP together with FUL significantly improved progression-free survival (PFS) in the PIK3CA-mutant ...

SOLAR-1 NEJM Publication. May 15, 2019 Novartis today announced the results from the global Phase III trial evaluating the investigational PI3K inhibitor were published in The New England Journal of Medicine.



Solar 1

The trial evaluated the efficacy and safety of the investigational PI3K inhibitor in postmenopausal women, and men, with hormone-receptor ...

Solar is a fluctuating industry that takes toughness and grit to stay around in. That's where 1Solar comes in. We've been around for over 10 years now and we know that we're not going anywhere. We're a full solar installation and solar repair/service company ready to tackle your solar project.

Treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with <i>PIK3CA</i>-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. (Funded by Novartis Pharmaceuticals; SOLAR-1 ClinicalTrials.gov number, NCT02437318.).

Solar 1 USA is a full-Turn Key company, offering our customers expert installation "EPC", sales, service and repairs. We are the leading company in our region for everything solar. We provide our customers with Premium Tier 1 products Made in USA and Germany.

Solar One is a 501c(3) organization that empowers communities in the New York City metro area to thrive in the face of the challenges brought on by climate change, and to embrace a world that is low carbon, resource efficient and socially inclusive. Solar One's mission is to design and deliver innovative education, training, and technical ...

a Characteristics are given as n (%) unless otherwise stated. b One man was enrolled in the PIQRAY + fulvestrant arm. All other study participants were postmenopausal women. c One patient randomized to placebo was not treated. d In the SOLAR-1 study, first line was defined as patients whose disease progressed <=1 year after (neo)adjuvant endocrine therapy (ET) or ...

KEY POINTS . In the final analysis of SOLAR-1, the PI3K inhibitor alpelisib given with fulvestrant yielded an 8-month gain in overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer with PIK3CA mutations, compared with fulvestrant alone. However, this difference did not meet the study's threshold for statistical ...

Methods: In the phase III, randomized, double-blind SOLAR-1 study (NCT02437318), men and postmenopausal women with HR+/HER2- advanced BC are randomized (1:1) to alpelisib or placebo (300 mg once daily) + fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1 [28 days], and Day 1 of Cycles >= 2) until disease progression or ...

The SOLAR-1 findings were presented during a satellite symposium at the 2019 European Society for Medical Oncology Breast Cancer Annual Congress in Berlin, Germany. The trial demonstrated the role of PIK3CA as a predictive marker for alpelisib's clinical efficacy, said Peter A. Fasching, MD, associate professor of gynecology and obstetrics at Friedrich ...



Solar 1

Alpelisib SOLAR-1 FINAL SCORE CURATIVE NON-CURATIVE Overall Survival / Disease-Free Survival / Pathological Complete Response INFORMATION Therapeutic Indication: Treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, locally advanced or MBC with a PIK3CA

In SOLAR-1, 572 postmenopausal women or men with HR-positive, HER2-negative advanced breast cancer were randomized to oral alpelisib (300 mg/day) or placebo plus intramuscular fulvestrant (500 mg every 28 days and on days 1 and 15 of treatment cycle 1).

Solar is a fluctuating industry that takes toughness and grit to stay around in. That's where 1Solar comes in. We've been around for over 10 years now and we know that we're not going anywhere. We're a full solar installation and solar ...

Solar One is a 501(c)(3) not-for-profit organization whose mission is to design and deliver innovative education, training, and technical assistance that fosters sustainability and resiliency in diverse urban environments. Programs. Green Design Lab Green Workforce Here Comes Solar ...

After a significant improvement in progression-free survival, final overall survival (OS) results of the SOLAR-1 trial could now demonstrate that alpelisib plus fulvestrant induces a clinically relevant improvement of eight months in OS for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation, as compared to fulvestrant alone. To date, alpelisib represents the ...

Solar 1 is New York City's only self-sustaining solar powered building. It houses educational facilities for Solar One, a non-profit organisation concerned with green energy, arts, and education. The Solar 1 building is located at the north end of Stuyvesant Cove Park, the city's only all-native plant park, which Solar 1 actively maintains. Situated on a brownfield site, Stuyvesant Cove Park offers opportunities for the local community to become involved in the park and learn about its s...

Find Solar One on Facebook; Find Solar One on ; Administrative Office 9-03 44th Road, 201 Long Island City, NY 11101. info@solar1 . 212.505.6050. ABOUT; CAREERS; CONTACT; BLOG; DONATE; Our Programs. Green Design Lab Green Workforce Here Comes Solar Stuyvesant Cove Park

Web: <https://wholesalesolar.co.za>